



General description

Cefalexin is a first-generation cephalosporin.

| | |
|--------------------|---|
| INN | Cefalexin |
| ATC codes | J01DB01 |
| Medicine type | Chemical agent |
| Antibiotic groups | A ACCESS |
| EML status history | <p>First added in 2009 (TRS 958) for Bacterial infection of unspecified site</p> <p>Added in 2017 (TRS 1006) for Acute pharyngitis</p> <p>Added in 2017 (TRS 1006) for Chronic obstructive pulmonary disease with acute exacerbation</p> <p>Added in 2017 (TRS 1006) for Bacterial cellulitis, erysipelas or lymphangitis</p> <p>Removed in 2017 (TRS 1006) for Bacterial infection of unspecified site</p> |
| Wikipedia | Cefalexin  |
| DrugBank | Cefalexin (Cephalexin)  |

Recommendations

Section Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)

Oral > Solid > dispersible tablet: 125 mg; 250 mg

Oral > Solid: 250 mg (as monohydrate)

Indications

First choice

Bacterial cellulitis, erysipelas or lymphangitis

Second choice

Acute pharyngitis

Chronic obstructive pulmonary disease with acute exacerbation

Other indications

Bacterial infection of unspecified site

